title: Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.
abstract: BACKGROUND
  The aim of this study was to investigate whether L-type amino acid transporter 1 (LAT1) expression can predict poor outcome after chemotherapy in patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Immunohistochemistry was carried out to examine the expression of LAT1, CD98, vascular endothelial growth factor (VEGF), Ki-67, phosphorylation of Akt (p-Akt), phosphorylation of mammalian target of rapamycin (p-mTOR) and p53 in resected lung tumor specimens obtained from 56 patients treated with platinum-based chemotherapy.
  
  
  RESULTS
  Positive LAT1 and CD98 expression was recognized in 45% (25/56) and 34% (19/56), respectively. In NSCLC (N=56), LAT1, CD98, VEGF, Ki-67 and p53 were significant factors for predicting poor outcome, and adenocarcinoma was an independent factor for predicting favorable prognosis. LAT1 expression was closely associated with chemoresistance. In adenocarcinoma (N=37), a statistically significant inverse relationship was observed between the expression of LAT1, VEGF and Ki-67 and epidermal growth factor receptor (EGFR) mutation, and positive expression of LAT1 and VEGF was an independent factor for predicting poor prognosis after chemotherapy.
  
  
  CONCLUSIONS
  LAT1 expression may be useful for predicting response and outcome after systemic chemotherapy.
authors: Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777, Japan. kkaira1970@yahoo.co.jp
authors: Kyoichi
authors: K
authors: Kaira
authors: Toshiaki
authors: T
authors: Takahashi
authors: Haruyasu
authors: H
authors: Murakami
authors: Takehito
authors: T
authors: Shukuya
authors: Hirotsugu
authors: H
authors: Kenmotsu
authors: Tateaki
authors: T
authors: Naito
authors: Noboru
authors: N
authors: Oriuchi
authors: Yoshikatsu
authors: Y
authors: Kanai
authors: Masahiro
authors: M
authors: Endo
authors: Haruhiko
authors: H
authors: Kondo
authors: Takashi
authors: T
authors: Nakajima
authors: Nobuyuki
authors: N
authors: Yamamoto
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D027261:Fusion Regulatory Protein-1 / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000378:metabolism; D027283:Large Neutral Amino Acid-Transporter 1 / Q000378:metabolism*; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000401:mortality / Q000628:therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D015996:Survival Rate; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D027261:Fusion Regulatory Protein-1; D019394:Ki-67 Antigen; D027283:Large Neutral Amino Acid-Transporter 1; D009944:Organoplatinum Compounds; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases